Results 191 to 200 of about 27,407 (265)

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open‐Label Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto, Ayumi Kanamoto, Takao Watanabe, Ryo Yano, Yuki Okazaki, Atsushi Yukimoto, Yoshiko Nakamura, Eiji Takeshita, Teru Kumagi, Yoichi Hiasa   +14 more
wiley   +1 more source

Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex. [PDF]

Diabetes Obes Metab
Yang C, Denig P, Chepulis L, Paul RG, Shin JI, Gansevoort RT, Vart P.   +6 more
europepmc   +1 more source

SURPASS‐CVOT and the Emerging Biology of Cardiometabolic Benefit

Diabetes, Obesity and Metabolism, EarlyView.
Salvatore Corrao, Francesco Cosentino, Massimo Federici   +2 more
wiley   +1 more source

Oral Butyrate Reduces Progression of Kidney Damage in an L‐NAME‐Induced Diabetic Kidney Disease Mouse Model

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Diabetic kidney disease (DKD) is one of the main causes of kidney failure worldwide. Interestingly, patients affected by DKD are characterised by a low abundance of gut bacteria producing short fatty acids including butyrate, which is suggested to play a role in the decline of renal function.
Maria Novella Nicese, Angela Koudijs, Reshma Lalai, Cristina Avramut, Rico J. E. Derks, Elena Sánchez‐López, Martin Giera, Amanda C. M. Pronk, Artemiy Kovynev, Sander Kooijman, Patrick C. N. Rensen, Roel Bijkerk, Bernard M. van den Berg, Joris I. Rotmans   +13 more
wiley   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study. [PDF]

Diabetes Obes Metab
Chen KE, Wang PC, Lin HA, Lin SF.
europepmc   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source

The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes. [PDF]

BMC Nephrol
Li C, Ng JKC, Chan GCK, Fung WWS, Chow KM, Szeto CC.   +5 more
europepmc   +1 more source

Multiple Effects of SGLT2 Inhibitors

JMA Journal
openaire   +2 more sources

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

Internal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes, Ingrid Hopper, Cathy Corbett, Felice Borghmans, Emma O'Donnell, Ana Slavnic, Genevieve Harvey, Elizabeth Rochford, Archana Thayaparan   +8 more
wiley   +1 more source

Non-Coding RNA in Type 2 Diabetes Cardio-Renal Complications and SGLT2 Inhibitor Response. [PDF]

Int J Mol Sci
Rykova E, Shmakova E, Damarov I, Merkulova T, Kzhyshkowska J.   +4 more
europepmc   +1 more source